Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARSCAPE Phase III Trial of PRM-151 in Idiopathic Pulmonary Fibrosis
jRCT2051210129Phase 3Suspended
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PRM-151 with Placebo (2 arms). Primary endpoint: Absolute change from baseline to Week 52 in forced vital capacity (FVC, mL). Started Mar 2022; status: suspended.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2051210129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210129.